ALNY News and Press, Alnylam Pharmaceuticals Inc. From 10/23/22

Summary Today is a great time to invest for the long run, though the market may very likely experience more volatility before once again resuming its march higher. We expect meaningful market share gains from most if not all of our investments. Returns from here will be powere...

Summary HQH is able to generate strong and steady yield which is good enough to ignore the price loss suffered by this fund in a market that’s bearish overall. HQH is in a better position to hold up to its current price, and as it trades at a good discount to its NAV, chanc...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The stock market has rallied nicely higher these past two days as investors refocus on the third-quarter earnings season, which, I might add, has gotten off to a strong start. According to FactSet, of the S&P 500 compan...

Summary Pharmaceuticals and biotechnology have the best value and quality scores. Healthcare providers look undervalued relative to 11-year averages. Other healthcare industries don’t look attractive. Focus on a biotech ETF: GNOM (and why I don’t like it). ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2022 on Thursday, October 27, 2022, before the U.S. financial markets open. Management will provi...

The U.S. Food and Drug Administration (FDA) approved the expanded use of Alnylam Pharmaceuticals ( NASDAQ: ALNY ) Oxlumo (lumasiran) subcutaneous injection for treating primary hyperoxaluria type 1 (PH1) to lower urinary oxalate (UOx) and plasma oxalate (POx) lev...

- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients - - Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of OXLUMO in PH1 Patients w...

Summary NTLA offers investors a unique opportunity to buy into an up-and-coming biotech company with impressive clinical data and the potential for future growth. Management continues executing their plan to respond to the confluence of events that alienated shareholders and pushe...

– New Data Further Support Potential for Patisiran to be an Effective Treatment for Cardiomyopathy of ATTR Amyloidosis – – Data from Exploratory Endpoints, Including Cardiac Biomarkers and Imaging, Suggest Favorable Impact of Patisiran on Measures of Cardi...

Summary The key catalyst for Travere in the near term is the PDUFA date for sparsentan for the treatment of IgA nephropathy in early November. With a positive outcome anticipated, there might not be enough reward to hold the stock into the event. Given the recent slow launches...